Arrivent Biopharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
ArriVent BioPharma reported increased research and development expenses in Q2 2026, alongside a substantial cash and investment balance, as it advances its pipeline of novel therapeutics.
NASDAQ
ArriVent BioPharma reports a reduced net loss for Q1 2026 compared to the prior year, with significant cash reserves bolstering its clinical-stage operations and drug development pipeline.
NASDAQ
ArriVent BioPharma reports increased R&D expenses and net losses in Q3 2025, driven by clinical trials and new collaborations, while maintaining a strong cash position.
NASDAQ
ArriVent BioPharma reported increased Q2 losses but highlighted positive firmonertinib clinical data, new oncology licenses, and a recent $81.1 million capital raise.
NASDAQ
10-Q: ArriVent BioPharma Reports Q1 2025 Financial Results, R&D Spending Soars Amid Pipeline Expansion
ArriVent BioPharma's Q1 2025 shows a significant increase in research and development expenses, driven by new collaborations and continued development of firmonertinib.
NASDAQ
ArriVent BioPharma's third quarter 2024 report highlights increased R&D spending, a net loss, and a strong cash position following its IPO.
NASDAQ
ArriVent BioPharma reports a net loss of $39.3 million for the first six months of 2024, alongside updates on clinical trials and collaborations.
NASDAQ
ArriVent BioPharma reports a net loss of $17.4 million for the first quarter of 2024, following its initial public offering in January.